Non Hodgkin Lymphoma Therapeutics Market & Pipeline Insight
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
The market for Non Hodgkin Lymphoma has significant unmet medical necessities in terms of demand for innovative drugs and novel technologies. This is one of the major factors behind the market witnessing rapid growth in Non Hodgkin Lymphoma segment. Past few decades have witnessed an increased level of activity with regards to development of new identification systems and drug mechanisms. In recent years, there have been an increasing number of pharmaceutical companies focusing their efforts on developing better and highly effective therapeutics for Non Hodgkin Lymphoma which are likely to occupy major market share in coming years.
Monoclonal antibodies (mAbs) for the treatment of Non Hodgkin Lymphoma has occupied large portion in global market. The highly versatile nature of mAbs makes them suitable for targeting different sub-categories of Non Hodgkin Lymphoma which is modestly provided by other therapeutics. The market of widely used chemotherapeutics is likely to decrease further as they are less effective and have more side effects as compared to mAbs. Present market shows that pharmaceutical companies are trying to capture large market portion by increasing indication of already available mAbs for other cancer categories.
Targeted therapies for Non Hodgkin Lymphoma have been able to make a significant place in global market. These therapeutics are generally based on inhibitors which targets signaling in the cancerous cells. Ibrutinib kinase inhibitor developed by Pharmacyclics and Johnson and Johnson’s sub-division Janssen Pharmaceuticals got market approval by the FDA in 2013 for the treatment of mantel cell lymphoma. In 2014, this drug also got the FDA’s approval for chronic lymphocytic leukemia in US market. It is expected that more targeted therapeutics will be available in coming years that would be able to provide effective medical care to patients and generate higher revenues for pharmaceutical companies.
The concepts of personalized cancer vaccines for Non Hodgkin Lymphoma have started emerging in global therapeutic market. These vaccines are widely accepted by oncologists and patients for having higher safety and efficacy levels. However, issues pertaining higher costs of newly developed personalized cancer vaccine is expected to decrease in near future. Technological advances have created higher confidences in pharmaceutical companies to make these medicines at higher manufacturing rates. This capability will help them to increase the market penetration of Non Hodgkin Lymphoma cancer vaccines.
With the recent technological advances, stem cell transplant has emerged as potent method for the treatment and cure of Non-Hodgkin. Oncologists are still trying to decipher the underlying principal of stem cell therapeutics as a treatment strategy. This method is expected to emerge as major section in market as the benefits provided outmatches any other products. It is expected that pharmaceutical companies would be able to overcome barriers in coming years before market introduction.
The market of Non Hodgkin Lymphoma is expected to make steady growth in coming years due to raising incidences and introduction of new therapeutics by pharmaceutical companies in global market. This largely untapped market has yet to witness the products which would be able to prevent, cure this disease, decrease morbidity and mortality rates. Large amount of money invested in research and development has started to show positive effect on pharmaceutical industry. As a result, the introductions of large amount of therapeutic products in coming years are expected to increase global market size of Non Hodgkin Lymphoma therapeutics.
“Non Hodgkin Lymphoma Therapeutics Market & Pipeline Insight” Report Highlight:
The market for Non Hodgkin Lymphoma has significant unmet medical necessities in terms of demand for innovative drugs and novel technologies. This is one of the major factors behind the market witnessing rapid growth in Non Hodgkin Lymphoma segment. Past few decades have witnessed an increased level of activity with regards to development of new identification systems and drug mechanisms. In recent years, there have been an increasing number of pharmaceutical companies focusing their efforts on developing better and highly effective therapeutics for Non Hodgkin Lymphoma which are likely to occupy major market share in coming years.
Monoclonal antibodies (mAbs) for the treatment of Non Hodgkin Lymphoma has occupied large portion in global market. The highly versatile nature of mAbs makes them suitable for targeting different sub-categories of Non Hodgkin Lymphoma which is modestly provided by other therapeutics. The market of widely used chemotherapeutics is likely to decrease further as they are less effective and have more side effects as compared to mAbs. Present market shows that pharmaceutical companies are trying to capture large market portion by increasing indication of already available mAbs for other cancer categories.
Targeted therapies for Non Hodgkin Lymphoma have been able to make a significant place in global market. These therapeutics are generally based on inhibitors which targets signaling in the cancerous cells. Ibrutinib kinase inhibitor developed by Pharmacyclics and Johnson and Johnson’s sub-division Janssen Pharmaceuticals got market approval by the FDA in 2013 for the treatment of mantel cell lymphoma. In 2014, this drug also got the FDA’s approval for chronic lymphocytic leukemia in US market. It is expected that more targeted therapeutics will be available in coming years that would be able to provide effective medical care to patients and generate higher revenues for pharmaceutical companies.
The concepts of personalized cancer vaccines for Non Hodgkin Lymphoma have started emerging in global therapeutic market. These vaccines are widely accepted by oncologists and patients for having higher safety and efficacy levels. However, issues pertaining higher costs of newly developed personalized cancer vaccine is expected to decrease in near future. Technological advances have created higher confidences in pharmaceutical companies to make these medicines at higher manufacturing rates. This capability will help them to increase the market penetration of Non Hodgkin Lymphoma cancer vaccines.
With the recent technological advances, stem cell transplant has emerged as potent method for the treatment and cure of Non-Hodgkin. Oncologists are still trying to decipher the underlying principal of stem cell therapeutics as a treatment strategy. This method is expected to emerge as major section in market as the benefits provided outmatches any other products. It is expected that pharmaceutical companies would be able to overcome barriers in coming years before market introduction.
The market of Non Hodgkin Lymphoma is expected to make steady growth in coming years due to raising incidences and introduction of new therapeutics by pharmaceutical companies in global market. This largely untapped market has yet to witness the products which would be able to prevent, cure this disease, decrease morbidity and mortality rates. Large amount of money invested in research and development has started to show positive effect on pharmaceutical industry. As a result, the introductions of large amount of therapeutic products in coming years are expected to increase global market size of Non Hodgkin Lymphoma therapeutics.
“Non Hodgkin Lymphoma Therapeutics Market & Pipeline Insight” Report Highlight:
- Global Non Hodgkin Lymphoma Market Overview
- Mechanism of Non Hodgkin Lymphoma Therapeutics
- Global Non Hodgkin Lymphoma Pipeline by Type, Phase & Company
- Global Non Hodgkin Lymphoma Pipeline: 204 Drugs
- Majority of the Drugs are in Phase-I: 54 Drugs
- Marketed Drugs for Non Hodgkin Lymphoma: 30 Drugs
- Patent Analysis by Country, Year & Compositions
1. INTRODUCTION TO NON HODGKIN LYMPHOMA
1.1 Low Grade Non Hodgkin Lymphomas-
1.2 High Grade Non Hodgkin Lymphomas
2. MECHANISM OF NON HODGKIN LYMPHOMA THERAPEUTICS
3. GLOBAL NON HODGKIN LYMPHOMA MARKET OVERVIEW
3.1 Current Market Scenario
3.2 Global Non Hodgkin Lymphoma Clinical Pipeline Overview
4. GLOBAL NON HODGKIN LYMPHOMA MARKET DYNAMICS
4.1 Favorable Market Parameters
4.2 Market Growth Challenges
4.3 Future Growth Outlook
5. FOLLICULAR LYMPHOMA CLINICAL PIPELINE INSIGHT BY PHASE, INDICATION, COMPANY & COUNTRY
5.1 Research till Phase-III
5.2 Discontinued Drug in Pipeline
6. NON HODGKIN LYMPHOMA CLINICAL PIPELINE INSIGHT BY PHASE, INDICATION, COMPANY & COUNTRY
6.1 Research till Registration
6.2 Marketed Drugs Clinical Insight
6.3 Suspended & Discontinued Drugs in Clinical Pipeline
7. B-CELL LYMPHOMA CLINICAL PIPELINE INSIGHT BY PHASE, INDICATION, COMPANY & COUNTRY
7.1 Preclinical till Phase-II
7.2 Discontinued Drugs in Clinical Pipeline
8. MANTLE CELL LYMPHOMA CLINICAL PIPELINE INSIGHT BY PHASE, INDICATION, COMPANY & COUNTRY
8.1 Preclinical till Phase-II
8.2 Discontinued Drugs in Clinical Pipeline
9. CUTANEOUS T CELL LYMPHOMA CLINICAL PIPELINE INSIGHT BY PHASE, INDICATION, COMPANY & COUNTRY
9.1 Preclinical till Phase-II
9.2 Marketed Drug Clinical Insight
9.3 Discontinued Drugs in Clinical Pipeline
10. CUTANEOUS B-CELL LYMPHOMA CLINICAL PIPELINE INSIGHT BY PHASE, INDICATION, COMPANY & COUNTRY
10.1 Phase: Preclinical
11. DIFFUSE LARGE B CELL LYMPHOMA CLINICAL PIPELINE INSIGHT BY PHASE, INDICATION, COMPANY & COUNTRY
11.1 Preclinical till Phase-II
11.2 Discontinued Drugs in Clinical Pipeline
12. T CELL LYMPHOMA CLINICAL PIPELINE INSIGHT BY PHASE, INDICATION, COMPANY & COUNTRY
12.1 Preclinical till Phase-II
12.2 Marketed Drugs Clinical Insight
12.3 Discontinued Drugs in Clinical Pipeline
13. MYCOSIS FUNGOIDES CLINICAL PIPELINE INSIGHT BY PHASE, INDICATION, COMPANY & COUNTRY
13.1 Phase-I
13.2 Marketed Drugs Clinical Insight
14. PERIPHERAL T-CELL LYMPHOMA CLINICAL PIPELINE INSIGHT BY PHASE, INDICATION, COMPANY & COUNTRY
14.1 Phase-II
15. MULTIPLE NON HODGKIN LYMPHOMA CLINICAL PIPELINE INSIGHT BY PHASE, INDICATION, COMPANY & COUNTRY
15.1 Preclinical till Registration
15.2 Marketed Drugs Clinical Insight
15.3 Discontinued Drugs in Clinical Pipeline
16. COMPETITIVE LANDSCAPE
16.1 Aryogen Biopharma
16.2 Biogen Idec
16.3 Biovest International
16.4 Chugai Pharmaceutical
16.5 Genetech
16.6 ImmunoGen
16.7 Johnson & Johnson
16.8 Novartis
16.9 Pfizer
16.10 Roche
1.1 Low Grade Non Hodgkin Lymphomas-
1.2 High Grade Non Hodgkin Lymphomas
2. MECHANISM OF NON HODGKIN LYMPHOMA THERAPEUTICS
3. GLOBAL NON HODGKIN LYMPHOMA MARKET OVERVIEW
3.1 Current Market Scenario
3.2 Global Non Hodgkin Lymphoma Clinical Pipeline Overview
4. GLOBAL NON HODGKIN LYMPHOMA MARKET DYNAMICS
4.1 Favorable Market Parameters
4.2 Market Growth Challenges
4.3 Future Growth Outlook
5. FOLLICULAR LYMPHOMA CLINICAL PIPELINE INSIGHT BY PHASE, INDICATION, COMPANY & COUNTRY
5.1 Research till Phase-III
5.2 Discontinued Drug in Pipeline
6. NON HODGKIN LYMPHOMA CLINICAL PIPELINE INSIGHT BY PHASE, INDICATION, COMPANY & COUNTRY
6.1 Research till Registration
6.2 Marketed Drugs Clinical Insight
6.3 Suspended & Discontinued Drugs in Clinical Pipeline
7. B-CELL LYMPHOMA CLINICAL PIPELINE INSIGHT BY PHASE, INDICATION, COMPANY & COUNTRY
7.1 Preclinical till Phase-II
7.2 Discontinued Drugs in Clinical Pipeline
8. MANTLE CELL LYMPHOMA CLINICAL PIPELINE INSIGHT BY PHASE, INDICATION, COMPANY & COUNTRY
8.1 Preclinical till Phase-II
8.2 Discontinued Drugs in Clinical Pipeline
9. CUTANEOUS T CELL LYMPHOMA CLINICAL PIPELINE INSIGHT BY PHASE, INDICATION, COMPANY & COUNTRY
9.1 Preclinical till Phase-II
9.2 Marketed Drug Clinical Insight
9.3 Discontinued Drugs in Clinical Pipeline
10. CUTANEOUS B-CELL LYMPHOMA CLINICAL PIPELINE INSIGHT BY PHASE, INDICATION, COMPANY & COUNTRY
10.1 Phase: Preclinical
11. DIFFUSE LARGE B CELL LYMPHOMA CLINICAL PIPELINE INSIGHT BY PHASE, INDICATION, COMPANY & COUNTRY
11.1 Preclinical till Phase-II
11.2 Discontinued Drugs in Clinical Pipeline
12. T CELL LYMPHOMA CLINICAL PIPELINE INSIGHT BY PHASE, INDICATION, COMPANY & COUNTRY
12.1 Preclinical till Phase-II
12.2 Marketed Drugs Clinical Insight
12.3 Discontinued Drugs in Clinical Pipeline
13. MYCOSIS FUNGOIDES CLINICAL PIPELINE INSIGHT BY PHASE, INDICATION, COMPANY & COUNTRY
13.1 Phase-I
13.2 Marketed Drugs Clinical Insight
14. PERIPHERAL T-CELL LYMPHOMA CLINICAL PIPELINE INSIGHT BY PHASE, INDICATION, COMPANY & COUNTRY
14.1 Phase-II
15. MULTIPLE NON HODGKIN LYMPHOMA CLINICAL PIPELINE INSIGHT BY PHASE, INDICATION, COMPANY & COUNTRY
15.1 Preclinical till Registration
15.2 Marketed Drugs Clinical Insight
15.3 Discontinued Drugs in Clinical Pipeline
16. COMPETITIVE LANDSCAPE
16.1 Aryogen Biopharma
16.2 Biogen Idec
16.3 Biovest International
16.4 Chugai Pharmaceutical
16.5 Genetech
16.6 ImmunoGen
16.7 Johnson & Johnson
16.8 Novartis
16.9 Pfizer
16.10 Roche
LIST OF FIGURES
Figure 1-1: Types of Blood Cancer
Figure 1-2: Identification of Different Types of Lymphomas
Figure 1-3: Classification Systems for Non Hodgkin Lymphoma
Figure 1-4: Grading of Non Hodgkin Lymphomas
Figure 1-5: Classification of Low Grade Non Hodgkin Lymphomas
Figure 1-6: Classification of High Grade Non Hodgkin Lymphomas
Figure 2-1: Mechanism of Monoclonal Antibodies for the Treatment of Non Hodgkin Lymphoma
Figure 2-2: Mechanism of Kinase Inhibitors for Treating Non- Hodgkin Lymphoma
Figure 2-3: Mode of Action of Non Hodgkin Lymphoma Vaccines
Figure 3-1: Non-Hodgkin Lymphoma Therapeutics Market (US$ Billion), 2014-2020
Figure 3-2: Folicular Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 3-3: Folicular Lymphoma Clinical Pipeline by Phase (Number), 2014
Figure 3-4: Discontinued Follicular Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 3-5: Discontinued Follicular Lymphoma Clinical Pipeline by Phase (Number), 2014
Figure 3-6: Non Hodgkin Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 3-7: Non Hodgkin Lymphoma Clinical Pipeline by Phase (Number), 2014
Figure 3-8: No Development Reported in Non Hodgkin Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 3-9: No Development Reported in Non Hodgkin Lymphoma Clinical Pipeline by Phase (Number), 2014
Figure 3-10: Discontinued Non Hodgkin Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 3-11: Discontinued Non Hodgkin Lymphoma Clinical Pipeline by Phase (Number), 2014
Figure 3-12: Suspended Non Hodgkin Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 3-13: Suspended Non Hodgkin Lymphoma Clinical Pipeline by Phase (Number), 2014
Figure 3-14: B-Cell Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 3-15: B-Cell Lymphoma Clinical Pipeline by Phase (Number), 2014
Figure 3-16: No Development Reported in B-Cell Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 3-17: No Development Reported in B-Cell Lymphoma Clinical Pipeline by Phase (Number), 2014
Figure 3-18: Discontinued B-Cell Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 3-19: Discontinued B-Cell Lymphoma Clinical Pipeline by Phase (Number), 2014
Figure 3-20: Mantle-Cell Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 3-21: Mantle-Cell Lymphoma Clinical Pipeline by Phase (Number), 2014
Figure 3-22: Cutaneous T-Cell Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 3-23: Cutaneous T-Cell Lymphoma Clinical Pipeline by Phase (Number), 2014
Figure 3-24: Discontinued Cutaneous T-Cell Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 3-25: Discontinued Cutaneous T-Cell Lymphoma Clinical Pipeline by Phase (Number), 2014
Figure 3-26: Diffuse Large B-Cell Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 3-27: Diffuse Large B-Cell Lymphoma Clinical Pipeline by Phase (Number), 2014
Figure 3-28: Discontinued Diffuse Large B-Cell Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 3-29: Discontinued Diffuse Large B-Cell Lymphoma Clinical Pipeline by Phase (Number), 2014
Figure 3-30: T-Cell Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 3-31: T-Cell Lymphoma Clinical Pipeline by Phase (Number), 2014
Figure 3-32: Mycosis Fungoides Clinical Pipeline by Phase (%), 2014
Figure 3-33: Mycosis Fungoides Clinical Pipeline by Phase (Number), 2014
Figure 3-34: Multiple Non Hodgkin Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 3-35: Multiple Non Hodgkin Lymphoma Clinical Pipeline by Phase (Number), 2014
Figure 3-36: Discontinued Multiple Non Hodgkin Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 3-37: Discontinued Multiple Non Hodgkin Lymphoma Clinical Pipeline by Phase (Number), 2014
Figure 4-1: Drivers for Non- Hodgkin Lymphoma Market
Figure 4-2: Challenges for Non- Hodgkin Lymphoma Market
Figure 1-1: Types of Blood Cancer
Figure 1-2: Identification of Different Types of Lymphomas
Figure 1-3: Classification Systems for Non Hodgkin Lymphoma
Figure 1-4: Grading of Non Hodgkin Lymphomas
Figure 1-5: Classification of Low Grade Non Hodgkin Lymphomas
Figure 1-6: Classification of High Grade Non Hodgkin Lymphomas
Figure 2-1: Mechanism of Monoclonal Antibodies for the Treatment of Non Hodgkin Lymphoma
Figure 2-2: Mechanism of Kinase Inhibitors for Treating Non- Hodgkin Lymphoma
Figure 2-3: Mode of Action of Non Hodgkin Lymphoma Vaccines
Figure 3-1: Non-Hodgkin Lymphoma Therapeutics Market (US$ Billion), 2014-2020
Figure 3-2: Folicular Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 3-3: Folicular Lymphoma Clinical Pipeline by Phase (Number), 2014
Figure 3-4: Discontinued Follicular Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 3-5: Discontinued Follicular Lymphoma Clinical Pipeline by Phase (Number), 2014
Figure 3-6: Non Hodgkin Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 3-7: Non Hodgkin Lymphoma Clinical Pipeline by Phase (Number), 2014
Figure 3-8: No Development Reported in Non Hodgkin Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 3-9: No Development Reported in Non Hodgkin Lymphoma Clinical Pipeline by Phase (Number), 2014
Figure 3-10: Discontinued Non Hodgkin Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 3-11: Discontinued Non Hodgkin Lymphoma Clinical Pipeline by Phase (Number), 2014
Figure 3-12: Suspended Non Hodgkin Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 3-13: Suspended Non Hodgkin Lymphoma Clinical Pipeline by Phase (Number), 2014
Figure 3-14: B-Cell Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 3-15: B-Cell Lymphoma Clinical Pipeline by Phase (Number), 2014
Figure 3-16: No Development Reported in B-Cell Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 3-17: No Development Reported in B-Cell Lymphoma Clinical Pipeline by Phase (Number), 2014
Figure 3-18: Discontinued B-Cell Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 3-19: Discontinued B-Cell Lymphoma Clinical Pipeline by Phase (Number), 2014
Figure 3-20: Mantle-Cell Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 3-21: Mantle-Cell Lymphoma Clinical Pipeline by Phase (Number), 2014
Figure 3-22: Cutaneous T-Cell Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 3-23: Cutaneous T-Cell Lymphoma Clinical Pipeline by Phase (Number), 2014
Figure 3-24: Discontinued Cutaneous T-Cell Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 3-25: Discontinued Cutaneous T-Cell Lymphoma Clinical Pipeline by Phase (Number), 2014
Figure 3-26: Diffuse Large B-Cell Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 3-27: Diffuse Large B-Cell Lymphoma Clinical Pipeline by Phase (Number), 2014
Figure 3-28: Discontinued Diffuse Large B-Cell Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 3-29: Discontinued Diffuse Large B-Cell Lymphoma Clinical Pipeline by Phase (Number), 2014
Figure 3-30: T-Cell Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 3-31: T-Cell Lymphoma Clinical Pipeline by Phase (Number), 2014
Figure 3-32: Mycosis Fungoides Clinical Pipeline by Phase (%), 2014
Figure 3-33: Mycosis Fungoides Clinical Pipeline by Phase (Number), 2014
Figure 3-34: Multiple Non Hodgkin Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 3-35: Multiple Non Hodgkin Lymphoma Clinical Pipeline by Phase (Number), 2014
Figure 3-36: Discontinued Multiple Non Hodgkin Lymphoma Clinical Pipeline by Phase (%), 2014
Figure 3-37: Discontinued Multiple Non Hodgkin Lymphoma Clinical Pipeline by Phase (Number), 2014
Figure 4-1: Drivers for Non- Hodgkin Lymphoma Market
Figure 4-2: Challenges for Non- Hodgkin Lymphoma Market
